SONN icon

Sonnet BioTherapeutics
SONN

Overview Fund Activity

23 hedge funds and large institutions have $2.11M invested in Sonnet BioTherapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 6 closing their positions.

Holders
23
Holders Change
+5
Holders Change %
+27.78%
% of All Funds
0.36%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
11
Increased
7
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SM
1
Sabby Management
Florida
$1.61M
2
Renaissance Technologies
2
Renaissance Technologies
New York
$144K
3
Geode Capital Management
3
Geode Capital Management
Massachusetts
$83K
4
State Street
4
State Street
Massachusetts
$46.3K
5
VF
5
Virtu Financial
New York
$42K

Top Sellers

1
AFM
1
Anson Funds Management
Texas
$0
2
Walleye Capital
2
Walleye Capital
New York
$0
3
Alyeska Investment Group
3
Alyeska Investment Group
Illinois
$0
4
AC
4
Ayrton Capital
Connecticut
$0
5
CH
5
CVI Holdings
Delaware
$0
Name Market Value Shares Shares
Change 		Shares
Change %
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
– – -951,806 Closed
AC
27
Ayrton Capital
Connecticut
– – -765,425 Closed
CH
28
CVI Holdings
Delaware
– – -701,634 Closed
BFM
29
Boothbay Fund Management
New York
– – -136,231 Closed
CFGS
30
Concourse Financial Group Securities
Alabama
– – – –
1
2